Gilead set to open $250m, 23-acre campus
pharmafile | August 15, 2017 | News story | Manufacturing and Production | Gilead, biotech, drugs, pharma, pharmaceutical
Gilead is set for the grand unveiling of its new facility in La Verne, Southern California, after several years of work. The facility, once it is running at full capacity, is it to create jobs for 500 workers.
The campus will initially focus on the manufacture of AmBisome, an antifungal medication that is used to combat fungal infections and a form of meningitis in people carrying HIV. As well as this, the campus will have the capacity to package, label and distribute other treatments owned by the company, including its hepatitis C treatments.
“Up to 14 million tablets will be packaged and up to 5 million AmBisome vials will be manufactured per year,” company spokesman Michele Rest was reported as saying to San Gabriel Valley Tribune. “Employee numbers in La Verne will increase as we build to full commercial operation.”
The majority of the campus is made up of one 320,000-square-foot building – that is actually made of five-interconnected buildings – but there is potential for further development in an 80,000-square-foot space.
The space will replace an existing manufacturing plant that is currently located in Sam Dimas. The two cities are direct neighbours, only three miles apart, meaning that current employees will not have to relocate to begin working at the new facility.
The new La Verne site will join two other California-based operations for the giant biotech, which also possesses operations in Oceanside and Fremont.
The ceremony to open the facility is expected to take place tomorrow and will be attended by CEO, John F. Milligan.
Ben Hargreaves
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Zumutor’s cancer drug trial cleared by FDA
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …
